



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Billot et al.

Serial No. 10/797,257

Filed: March 10, 2004

For: EP4 Receptro Agonist , Compositions and Methods
ThereofArt Unit: 1614Examiner: To be AssignedCommissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

4. Pursuant to the waiver by the Office of the requirement under 37 CFR 1.98 (a)(2)(i) dated July 11, 2003, if the filing date of this application is after June 30, 2003, copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

By *[Signature]* **MERCK & CO., INC.** Date 10/12/2004

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

By: Sylvia A. Ayler

Attorney For Applicant(s)

Reg. No. 36,436

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594- 4909

Date: October 12, 2004

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use ~~as~~ many sheets as necessary)

COMPLETE IF KNOWN

Application Number	10/797,257
Filing Date	March 10, 2004
First Named Inventor	Billot et al.
Group Art Unit	1614
Examiner Name	To be Assigned
Attorney Docket Number	MC080Y

1

of

3

Attorney Docket Number	MC080Y
------------------------	--------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
		K.	WO 02/24647	A1	Ono Pharmaceutical	03/28/2002
		L.	WO 02/42268	A2	Pfizer Products Inc.	05/30/2002
		M.	EP 1114816	A1	Ono Pharmaceutical	07/11/2001
		N.	WO 01/46140	A1	Pfizer Products Inc.	06/28/2001
		O.	WO 03/105868	A1	Merck & Co. Inc.	12/24/2003
		P.	WO 03/105724		Merck & Co. Inc.	12/24/2003
		Q.	WO 03/105847	A1	Merck & Co. Inc.	12/24/2003
		R.	WO 02/060863	A1	Merck & Co. Inc.	08/08/2002
		S.	GB 1 524 818		Beecham Group Ltd.	11/29/1974
		T.	WO 01/72268	A2	Merck & Co.	10/03/2002

Examiner
Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

(use as many sheets as necessary)

Sheet

2

of

3

Application Number

Filing Date**First Named Inventor**

Group Art Unit

Examiner Name

Attorney Docket Number

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	U.		WO 94/13275	A1	Massachusetts Eye and Ear Infirmary	06/23/1994
	V.		WO 01/70702	A1	Alcon Universal Ltd.	09/27/2001
	X.		WO 00/21542	A1	Merck & Co. Inc.	04/20/2000
	Y.		EP0855389	B1	Ono Pharmaceutical	01/26/1998
	Z.		WO 03/047417	A2	Merck & Co. Inc.	06/12/2003
	AA.		WO 03/047513	A2	Merck & Co. Inc.	06/12/2003
	BB.		EP 0 008 186	A1	Beecham Group Limited	07/30/1979
	CC.		WO 02/077168	A2	Merck & Co. Inc.	10/03/2002

Examiner
Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/797,257	
			Filing Date	March 10, 2004	
			First Named Inventor	Billot et al.	
			Group Art Unit	1614	
			Examiner Name	To be Assigned	
Sheet	3	of	3	Attorney Docket Number	MC080Y

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	DD.	P. Barraclough et al., "Heterocyclic Prostaglandin Analogues. Part 4, Piperazine-2,5-diones, Pyrazolidine-3,5-diones, 1,2,4-Triazolidinediones, 1,3,4-Oxadiazolidine-diones and 1,3,4-Thiadiazolidinediones", 1980, pp. 2096-2105, J.C.S. Perkin I.
	EE.	R. A. Schumer et al., "The Nerve of Glaucoma", 1994, pp. 37-44, Vol. 112, Arch Ophthalmol.
	FF.	M. Weinreb et al., "Different Pattern of Alkaline Phosphatase, Osteopontin, and Osteocalcin Expression in Developing Rat Bone Visualized by in Situ Hybridization", 1990, Vol. 5, No. 8, J. of Bone and Mineral Research.
	GG.	D. A. Dartt et al., "Localization of Nerves Adjacent to Goblet Cells in Rat Conjunctiva" 1994, pp. 993-1000, Vol. 14, Curr. Eye Res.
	HH.	L. Dandona et al., "Selective Effects of Experimental Glaucoma on Axonal Transport by Retinal Ganglion Cells to the Dorsal Lateral Geniculate Nucleus", 1991, pp. 1593-1599, Vol. 32, No. 5, Investigative Ophthalmology & Visual Sciences.
	II.	E. M. Ross, "Mechanisms of Drug Action and the Relationship Between Drug Concentration and Effect", pp. 29-41, chapter 2, Goodman and Gilman's Pharmacological Basis of Therapeutics.
	JJ.	I. K. Gipson et al., "Mucin Genes Expressed by the Ocular Surface Epithelium", 1997, pp. 81-98, Vol 16, No. 1, Progress in Retinal and Eye Research.
	KK.	D. M. Shinar et al., "Expression of alphaV and Beta Integrin Subunits in Rat Osteoclasts in Situ", 1993, pp. 403-414, Vol. 8, No. 4, J. of Bone and Mineral Research.
	LL.	M. A. Lemp et al., "Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes", 1995, pp. 221-232, Vol. 21, No. 4, CLAO Journal.
	MM.	M. Abramovitz et al., "The Utilization of Recombinant Prostanoid Receptors to Determine the Affinities and Selectivities of Prostaglandins and Related Analogs", 2000, pp. 285-293, Vol. 1483, Biochimica et Biophysica Acta.
	NN.	P. Chomczynski et al., "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction", 1987, pp. 156-159, Vol. 162, Analytical Biochemistry.
	OO.	S.B. Rodan et al., "Growth Stimulation of Rat Calvaria Osteoblastic Cells by Acidic Fibroblast Growth Factor", 1987, pp.1917-1923, Vol. 121, No. 6, Endocrinology.
	PP.	M. Abramovitz et al., "Human Prostanoid Receptors: Cloning and Characterization", 1995, pp. 499-504, Vol. 23, Advances in Prostaglandin Thromboxane, and Leukotriene Research.
	QQ.	J. E. Larco et al., "Epithelioid and Fibroblastic Rat Kidney Cell Clones: Epidermal Growth Factor (EGF) Receptors and the Effect of Mouse Sarcoma Virus Transformation", 1978, pp.335-342, Vol. 94, J. Cell Physiol.
	RR.	T. J. Hodgkinson et al., "Practical Asymmetric Synthesis of Both Enantiomers of 6-(Hydroxymethyl) piperidin-2-one", pp. 1141-1144, Synthesis.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003